株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の再生医療市場:2017年〜2021年

Regenerative Medicine Market in the US 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 277867
出版日 ページ情報 英文 107 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.74円で換算しております。
Back to Top
米国の再生医療市場:2017年〜2021年 Regenerative Medicine Market in the US 2017-2021
出版日: 2017年07月26日 ページ情報: 英文 107 Pages
概要

再生医療は、ヒトの細胞、組織、または臓器の治療のために、治療用に誘発された、もしくは研究室で培養されたヒトの組織を利用するプロセスを扱っています。それは疾患や怪我を治療する媒体として、正常に機能していない、または損傷した細胞に代わる新たな細胞を生み出すのを手伝う、新たな治療の分野です。多様な疾患の治療における利用が期待されていることから、米国における再生医療市場は、2017-2021年の期間においてCAGR (複合年間成長率) 23.53%で成長することが見込まれています。

当レポートでは、米国の再生医療市場を取り上げ、遺伝子治療および市場の概要、パイプライン製品の状況、規制状況、市場発展促進要因、市場における課題、ならびにそれらの影響を概括し、製品別・用途別に市場の現状と見通しについて調査分析するとともに、主なベンダーのプロファイルをまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場調査手法

第4章 イントロダクション

  • 米国市場における再生医療

第5章 市場情勢

  • 市場概要
  • 市場規模・予測

第6章 パイプラインポートフォリオ

  • ファイブフォース分析

第7章 市場区分:製品別

  • 米国の細胞治療市場
  • 米国のスキャホールド (足場) 市場

第8章 市場区分:用途別

  • 皮膚科学
  • 筋骨格系
  • 眼球
  • 心血管

第9章 市場区分:エンドユーザー別

  • 病院
  • 外来外科センター(ASC)
  • 再生医療センター

第10章 意思決定構造

第11章 市場発展促進要因と課題

第12章 市場動向

第13章 ベンダー情勢

  • 競合シナリオ

第14章 主要ベンダーの分析

  • Acelity
  • Medtronic
  • MiMedx Group
  • Organogenesis
  • Zimmer Biomet
  • その他の主要なベンダー

第15章 付録

  • 略語集

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR13871

About Regenerative Medicine Market in the US

Regenerative medicine is a bioproduct, which is developed by using translational research techniques such as molecular biology, tissue engineering, and gene engineering. Stem cells and tissue scaffolds have the effective therapeutic potential, which has increased the adoption of regenerative medicine in the US market. Stem cell therapy responds well to various treatments such as dermatological, macular, musculoskeletal, and cardiovascular applications. The regenerative medicine industry includes four key sectors, which help the vendors to develop regenerative medicine.

Technavio's analysts forecast the Regenerative Medicine Market in the US to grow at a CAGR of 23.53% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the Regenerative Medicine Market in the US for 2017-2021. To calculate the market size, the report considers the sales, volume, and value of regenerative medicine market in the US.

Technavio's report, Regenerative Medicine Market in the US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Acelity
  • Medtronic
  • MiMedx
  • Organogenesis
  • Zimmer Biomet

Other Prominent Vendors

  • ACE Surgical Supply
  • Acera Surgical
  • Acologix
  • Advanced Biologics
  • AlloCure
  • AlloSource
  • Alphatec Spine
  • ANTEROGEN
  • Antibe Therapeutics
  • Astellas Pharma
  • Athersys
  • Avita Medical
  • AxoGen
  • Bacterin International
  • Baxter
  • Bellicum Pharmaceuticals
  • BioCardia
  • Biogen
  • BioRestorative Therapies
  • Biostage
  • Bio-Tissue
  • BioTissue
  • bluebird bio
  • BONESUPPORT
  • BrainStorm Cell Therapeutics
  • Caladrius
  • Calimmune
  • Capricor Therapeutics
  • CELGENE
  • Cell Medica
  • Cell Therapy
  • CellBioMed
  • CellSeed
  • Celyad
  • CESCA THERAPEUTICS
  • CTM CRC
  • CryoLife
  • Cynata
  • Cytori Therapeutics
  • Dendreon Pharmaceuticals
  • DiscGenics
  • Fate Therapeutics
  • Fibrocell Science
  • Forticell Bioscience
  • Fortress Biotech
  • FUJIFILM Holdings
  • Gamida Cell
  • Geron
  • GlaxoSmithKline
  • Healthpoint (acquired by Smith & Nephew)
  • Histogen
  • Histogenics
  • Holostem Terapie Avanzate
  • Humacyte
  • Immunocellular Therapeutics
  • Integra LifeSciences
  • Intercytex
  • InVivo Therapeutics
  • iSTO Biologics
  • Janssen Pharmaceuticals
  • Juno Therapeutics
  • Juventas Therapeutics
  • Kiadis Pharma
  • LifeCell
  • LifeNet Health
  • Living Cell Technologies
  • Lonza
  • MaxCyte
  • MEDIPOST
  • Mesoblast
  • Nanofiber Solutions
  • Nanotope
  • Neuralstem
  • NewLink Genetics
  • Northwest Biotherapeutics
  • NovaRx
  • Opexa Therapeutics
  • ORGANOVO HOLDINGS
  • Orteq
  • Orthofix Holdings
  • Osiris Therapeutics
  • Pfizer
  • PHARMICELL
  • Pluristem
  • Prima BioMed
  • Q Therapeutics
  • Regenerex
  • Regenerys
  • Regience
  • Regrow
  • RENOVA THERAPEUTICS
  • RepliCel
  • ReproCELL
  • RhinoCyte
  • Rohto Pharma
  • RTI Surgical
  • SanBio
  • Sangamo Therapeutics
  • Shanghai Sunway Biotech
  • Shire
  • Stratatech
  • SURGILOGIX
  • Synergistic Technologies
  • TAKARA BIO
  • tella
  • Tissue Genesis
  • TissueGene
  • Txcell
  • VentriNova
  • Vericel
  • ViaCyte
  • VistaGen Therapeutics

Market driver

  • CVD and diabetes in young adult and aging population
  • For a full, detailed list, view our report

Market challenge

  • High cost of clinical trial
  • For a full, detailed list, view our report

Market trend

  • Increasing strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Overview of regenerative medicine in the US market

PART 05: Market landscape

  • Market overview
  • Market size and forecast

PART 06: Pipeline portfolio

  • Five forces analysis

PART 07: Market segmentation by product

  • Cell therapy market in US
  • Tissue scaffolds market in US

PART 08: Market segmentation by application

  • Dermatological
  • Musculoskeletal
  • Ocular
  • Cardiovascular

PART 09: Market segmentation by end-user

  • Hospitals
  • ASCs
  • Regenerative medicine centers

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Increasing strategic alliances
  • Increasing number of regenerative medicine in product line
  • Gene therapy trending toward market expansion

PART 13: Vendor landscape

  • Competitive landscape

PART 14: Key vendor analysis

  • Acelity
  • Medtronic
  • MiMedx Group
  • Organogenesis
  • Zimmer Biomet
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Overview of key sectors involved in regenerative medicine
  • Exhibit 02: SBIR and STTR programs
  • Exhibit 03: Regenerative medicine market in US 2016-2021 ($ billions)
  • Exhibit 04: Pipeline of regenerative medicines for CVDs
  • Exhibit 05: Pipeline of regenerative medicines for central nervous system, orthopedic, and ocular disorders
  • Exhibit 06: Pipeline of regenerative medicines for dermatology and diabetes
  • Exhibit 07: Pipeline of regenerative medicines for oncology
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Regenerative medicine market in US by product
  • Exhibit 10: Regenerative medicine market in US by product 2016 and 2021 ($ billions)
  • Exhibit 11: Ethical issues involved in different cell therapy research categories
  • Exhibit 12: Key cell therapy products marketed in US
  • Exhibit 13: Cell therapy market in US 2016-2021 ($ billions)
  • Exhibit 14: Market dynamics: Cell therapy market in US
  • Exhibit 15: Collaborations for R&D of tissue scaffold
  • Exhibit 16: Tissue scaffolds market in US 2016-2021 ($ millions)
  • Exhibit 17: Recent M&A in tissue scaffolds market
  • Exhibit 18: Market dynamics: Tissue scaffolds market in US
  • Exhibit 19: Regenerative medicine market in US by application 2016 (%)
  • Exhibit 20: Market growth: Regenerative medicine market in US by application
  • Exhibit 21: Overview of dermatological in regenerative medicine market in US
  • Exhibit 22: Target population and market growth opportunity
  • Exhibit 23: Pipeline of regenerative medicine for dermatological
  • Exhibit 24: Overview of musculoskeletal in regenerative medicine market in US
  • Exhibit 25: Regenerative medicine for occupational injury and sports injury
  • Exhibit 26: Pipeline of regenerative medicine for musculoskeletal
  • Exhibit 27: Overview of ocular in regenerative medicine market in US
  • Exhibit 28: Market overview of CVDs in US
  • Exhibit 29: Overview of cardiovascular in regenerative medicine market in US
  • Exhibit 30: Regenerative medicine market in US by end-users 2016
  • Exhibit 31: Segmentation of hospitals based on number of beds
  • Exhibit 32: Revenues funded by federal agencies for regenerative medicine research in 2014 ($ millions)
  • Exhibit 33: Estimated budget of funding for research in regenerative medicines 2012-2017 ($ millions)
  • Exhibit 34: Regulatory challenges in regenerative product market
  • Exhibit 35: Major strategic alliances in regenerative medicine market globally
  • Exhibit 36: Some of the mid and late stage pipeline products for regenerative medicine
  • Exhibit 37: Competitive structure analysis of regenerative medicine market in US 2016
  • Exhibit 38: Competitive landscape of regenerative medicine market in US 2016
  • Exhibit 39: Strategies for large and small companies in regenerative medicine market in US
  • Exhibit 40: Key recommendations for new entrants in regenerative medicine market in US
  • Exhibit 41: Acelity: Key highlights
  • Exhibit 42: Acelity: Strength assessment
  • Exhibit 43: Acelity: Strategy assessment
  • Exhibit 44: Acelity: Opportunity assessment
  • Exhibit 45: Medtronic: Key highlights
  • Exhibit 46: Medtronic: Strength assessment
  • Exhibit 47: Medtronic: Strategy assessment
  • Exhibit 48: Medtronic: Opportunity assessment
  • Exhibit 49: MiMedx Group: Key highlights
  • Exhibit 50: MiMedx Group: Strength assessment
  • Exhibit 51: MiMedx Group: Strategy assessment
  • Exhibit 52: MiMedx Group: Opportunity assessment
  • Exhibit 53: Organogenesis: Key highlights
  • Exhibit 54: Organogenesis: Strength assessment
  • Exhibit 55: Organogenesis: Strategy assessment
  • Exhibit 56: Organogenesis: Opportunity assessment
  • Exhibit 57: Zimmer Biomet: Key highlights
  • Exhibit 58: Zimmer Biomet: Strength assessment
  • Exhibit 59: Zimmer Biomet: Strategy assessment
  • Exhibit 60: Zimmer Biomet: Opportunity assessment
  • Exhibit 61: Other prominent vendors: Regenerative medicine market in US
Back to Top